Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-28 00:07 | 2023-02-23 | VERA | Vera Therapeutics, Inc. | SEIDENBERG BETH C | Director | Pharmaceutical Preparations | BUY | $7.24 | 200 | $1,447 | 1,664,902 | +0.0% |
| 2023-02-18 00:19 | 2023-02-06 | VERA | Vera Therapeutics, Inc. | Young Joseph R | Officer; SVP, Finance, Chief Acct Offcr | Pharmaceutical Preparations | BUY | $7.00 | 5,714 | $39,998 | 22,679 | +33.7% |
| 2023-02-18 00:17 | 2023-02-06 | VERA | Vera Therapeutics, Inc. | Grant Sean | Officer; Chief Financial Officer | Pharmaceutical Preparations | BUY | $7.00 | 14,285 | $99,995 | 49,933 | +40.1% |
| 2023-02-16 02:32 | 2023-02-13 | VERA | Vera Therapeutics, Inc. | SEIDENBERG BETH C | Director | Pharmaceutical Preparations | BUY | $7.20 | 10,072 | $72,490 | 1,664,702 | +0.6% |
| 2023-02-14 00:04 | 2023-02-09 | VERA | Vera Therapeutics, Inc. | SEIDENBERG BETH C | Director | Pharmaceutical Preparations | BUY | $7.25 | 400 | $2,900 | 1,654,630 | +0.0% |
| 2023-02-10 00:36 | 2023-02-03 | VERA | Vera Therapeutics, Inc. | SEIDENBERG BETH C | Director | Pharmaceutical Preparations | BUY | $7.10 | 311,078 | $2,209,587 | 1,654,230 | +23.2% |
| 2023-02-09 00:05 | 2022-02-06 | VERA | Vera Therapeutics, Inc. | Young Joseph R | Officer; SVP, Finance, Chief Acct Offcr | Pharmaceutical Preparations | BUY | $7.00 | 5,714 | $39,998 | 22,679 | +33.7% |
| 2023-02-09 00:04 | 2022-02-06 | VERA | Vera Therapeutics, Inc. | Grant Sean | Officer; Chief Financial Officer | Pharmaceutical Preparations | BUY | $7.00 | 14,285 | $99,995 | 49,933 | +40.1% |
| 2023-02-09 03:40 | 2023-02-06 | VERA | Vera Therapeutics, Inc. | Longitude Capital Partners IV, LLC | 10% owner | Pharmaceutical Preparations | BUY | $7.00 | 1,714,285 | $11,999,995 | 1,714,285 | +100.0% |
| 2023-02-09 03:32 | 2023-02-06 | VERA | Vera Therapeutics, Inc. | ENRIGHT PATRICK G | Director, 10% owner | Pharmaceutical Preparations | BUY | $7.00 | 1,714,285 | $11,999,995 | 1,714,285 | +100.0% |
| 2023-02-09 02:29 | 2023-02-06 | VERA | Vera Therapeutics, Inc. | Sofinnova Venture Partners X, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $7.00 | 285,714 | $1,999,998 | 3,467,156 | +9.0% |
| 2022-12-20 01:01 | 2022-12-16 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $19.49 | 2,212 | $43,116 | 26,821 | -7.6% |
| 2022-12-15 00:08 | 2022-12-12 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $18.26 | 19,711 | $359,972 | 26,821 | -42.4% |
| 2022-12-09 00:06 | 2022-12-07 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | SALE | $16.47 | 494 | $8,136 | 26,821 | -1.8% |
| 2022-11-22 00:08 | 2022-11-17 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $15.85 | 3,289 | $52,128 | 27,315 | -10.7% |
| 2022-11-11 00:04 | 2022-11-09 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | SALE | $16.54 | 494 | $8,171 | 27,315 | -1.8% |
| 2022-10-20 23:37 | 2022-10-18 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $19.41 | 8,590 | $166,735 | 27,809 | -23.6% |
| 2022-10-06 23:04 | 2022-10-05 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | SALE | $21.64 | 988 | $21,380 | 27,809 | -3.4% |
| 2022-10-05 23:05 | 2022-10-03 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Director, Officer; President and CEO | Pharmaceutical Preparations | OPT+S | $20.90 | 32,000 | $668,774 | 181,150 | -15.0% |
| 2022-09-22 23:06 | 2022-09-20 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $20.72 | 16,840 | $348,943 | 28,797 | -36.9% |
| 2022-09-14 23:12 | 2022-09-13 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Director, Officer; President and CEO | Pharmaceutical Preparations | OPT+S | $21.16 | 22,363 | $473,237 | 181,150 | -11.0% |
| 2022-09-13 23:04 | 2022-09-09 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Director, Officer; President and CEO | Pharmaceutical Preparations | OPT+S | $20.43 | 29,022 | $592,812 | 181,150 | -13.8% |
| 2022-09-09 23:23 | 2022-09-07 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Director, Officer; President and CEO | Pharmaceutical Preparations | OPT+S | $20.37 | 21,891 | $445,878 | 181,150 | -10.8% |
| 2022-09-08 23:41 | 2022-09-07 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | SALE | $18.63 | 988 | $18,406 | 28,797 | -3.3% |
| 2022-09-06 23:29 | 2022-09-01 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Director, Officer; President and CEO | Pharmaceutical Preparations | OPT+S | $21.09 | 34,196 | $721,235 | 181,150 | -15.9% |
| 2022-08-23 23:15 | 2022-08-19 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $19.13 | 8,539 | $163,389 | 29,785 | -22.3% |
| 2022-08-19 23:39 | 2022-08-17 | VERA | Vera Therapeutics, Inc. | Carlyle Group Inc. | 10% owner | Pharmaceutical Preparations | OPT+S | $20.25 | 9,925 | $201,026 | 2,960,231 | -0.3% |
| 2022-08-15 23:11 | 2022-08-12 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Director, Officer; President and CEO | Pharmaceutical Preparations | OPT+S | $20.16 | 20,528 | $413,799 | 137,400 | -13.0% |
| 2022-08-04 23:07 | 2022-08-03 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | SALE | $16.81 | 988 | $16,608 | 17,285 | -5.4% |
| 2022-07-20 23:08 | 2022-07-19 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $16.01 | 11,444 | $183,271 | 18,273 | -38.5% |
| 2022-07-15 23:41 | 2022-07-14 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $15.14 | 9,104 | $137,864 | 18,273 | -33.3% |
| 2022-07-11 23:04 | 2022-07-07 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $15.05 | 9,666 | $145,453 | 21,023 | -31.5% |
| 2022-06-24 01:49 | 2022-06-22 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $15.01 | 1,545 | $23,198 | 23,688 | -6.1% |
| 2022-06-22 03:16 | 2022-06-17 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $15.04 | 5,887 | $88,565 | 23,994 | -19.7% |
| 2022-06-16 23:06 | 2022-06-15 | VERA | Vera Therapeutics, Inc. | Grant Sean | Officer; Chief Financial Officer | Pharmaceutical Preparations | BUY | $13.60 | 5,000 | $68,004 | 992 | +100.0% |
| 2022-06-02 23:06 | 2022-05-31 | VERA | Vera Therapeutics, Inc. | Curley Joanne | Officer; Chief Development Officer | Pharmaceutical Preparations | OPT+S | $15.22 | 400 | $6,086 | 25,194 | -1.6% |
| 2022-04-05 14:24 | 2022-02-10 | VERA | Vera Therapeutics, Inc. | Longitude Capital Partners IV, LLC | 10% owner | Pharmaceutical Preparations | BUY | $15.00 | 333,333 | $4,999,995 | 3,429,927 | +10.8% |
| 2022-04-05 14:22 | 2022-02-10 | VERA | Vera Therapeutics, Inc. | ENRIGHT PATRICK G | Director, 10% owner | Pharmaceutical Preparations | BUY | $15.00 | 333,333 | $4,999,995 | 3,429,927 | +10.8% |
| 2022-02-15 02:17 | 2022-02-10 | VERA | Vera Therapeutics, Inc. | Sofinnova Venture Partners X, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $15.00 | 266,666 | $3,999,990 | 3,181,442 | +9.1% |
| 2021-05-19 03:17 | 2021-05-18 | VERA | Vera Therapeutics, Inc. | Katabi Maha | Director, 10% owner | Pharmaceutical Preparations | BUY | $11.00 | 727,272 | $7,999,992 | 2,914,776 | +33.2% |
| 2021-05-19 03:20 | 2021-05-18 | VERA | Vera Therapeutics, Inc. | Longitude Capital Partners IV, LLC | 10% owner | Pharmaceutical Preparations | BUY | $11.00 | 909,090 | $9,999,990 | 3,096,594 | +41.6% |
| 2021-05-19 01:00 | 2021-05-18 | VERA | Vera Therapeutics, Inc. | Abingworth LLP | 10% owner | Pharmaceutical Preparations | BUY | $11.00 | 772,727 | $8,499,997 | 2,960,231 | +35.3% |
| 2021-05-19 03:14 | 2021-05-18 | VERA | Vera Therapeutics, Inc. | ENRIGHT PATRICK G | Director, 10% owner | Pharmaceutical Preparations | BUY | $11.00 | 909,090 | $9,999,990 | 3,096,594 | +41.6% |
| 2021-05-19 03:10 | 2021-05-17 | VERA | Vera Therapeutics, Inc. | EMSTER KURT VON | Director | Pharmaceutical Preparations | BUY | $11.02 | 790,555 | $8,714,683 | 2,960,231 | +36.4% |
| 2021-05-19 03:23 | 2021-05-18 | VERA | Vera Therapeutics, Inc. | Sofinnova Venture Partners X, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $11.00 | 727,272 | $7,999,992 | 2,914,776 | +33.2% |
| 2011-11-17 23:37 | 2011-11-08 | VERA | N/A | COLLINS SETH | Director | Other | BUY | $0.50 | 10,000 | $5,000 | 90,000 | +12.5% |
| 2011-11-14 15:55 | 2011-09-22 | VERA | N/A | COLLINS SETH | Director | Other | BUY | $0.49 | 30,000 | $14,625 | 80,000 | +60.0% |
| 2011-09-21 18:13 | 2011-09-20 | VERA | N/A | Mazzullo Anthony C | Officer; CEO & President | Other | BUY | $0.46 | 6,000 | $2,760 | 210,820 | +2.9% |
| 2011-08-10 22:52 | 2011-08-09 | VERA | N/A | Mazzullo Anthony C | Officer; CEO & President | Other | BUY | $0.50 | 500 | $250 | 204,820 | +0.2% |
| 2010-01-05 19:02 | 2009-12-31 | VERA | N/A | COLLINS SETH | Director | Other | BUY | $0.25 | 10,100 | $2,525 | 50,000 | +25.3% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.